美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Lpath

2.94

-0.0701-2.33%

成交量：1.47萬

成交額：4.31萬

市值：- -

市盈率：- -

高：3.02

開：3.02

低：2.93

收：3.01

52周最高：5.88

52周最低：1.68

股本：- -

流通股本：- -

量比：- -

換手率：- -

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Lpath

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.lpath.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Lpath, Inc.是一家生物科技公司，專註於脂類基礎治療性抗體的開發與研究，這是一個醫療科學的新興領域，針對帶有生物活性的信號脂質來治療一系列人類疾病。公司目前有兩個候選產品位於臨床開發階段，一個產品位於臨床前評估階段。 Lpath, Inc是發現和開發中和生物活性脂質的單克隆抗體的行業領跑者。脂質研究（稱作lipidomics）是一個新興研究領域，目前已經發現的具有生物活性會促成疾病的有幾十個，如果在該領域的資金繼續投入的話，還將有數百個相關發現。一旦引起疾病的脂質確定下來接下來的挑戰就是生產一種能中和相關生物活性脂質的複合物。通過其免疫Y2平台技術和強大的專利財產，Lpath處在唯一能夠面對這些挑戰，利用機遇的地位。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/LPTN/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LPTN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LPTN\",,,,,undefined,":{"symbol":"LPTN","market":"US","secType":"STK","nameCN":"Lpath","latestPrice":2.94,"timestamp":1483045200000,"preClose":3.0101,"halted":0,"volume":14706,"delay":0,"changeRate":-0.02328826284841037,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-0.0701,"latestTime":"03-25 15:53:36 EDT","open":3.02,"high":3.02,"low":2.93,"amount":43088.58,"amplitude":0.029899,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1774468800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.0101,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LPTN\",,,,,undefined,":{"symbol":"LPTN","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":3.02,"amplitude":0.029899,"preClose":3.0101,"low":2.93,"week52Low":1.68,"pbRate":"--","week52High":5.88,"institutionHeld":0,"latestPrice":2.94,"eps":0,"divideRate":0,"volume":14706,"delay":0,"open":3.02,"prevYearClose":16.115},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LPTN\",params:#limit:5,,,undefined,":[{"date":"2016-12-30","symbol":"LPTN","reason":"合并为APEN","type":"delisting","dateTimestamp":1483074000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LPTN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LPTN\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.lpath.com","stockEarnings":[{"period":"1week","weight":-0.8176},{"period":"1month","weight":-0.8176},{"period":"3month","weight":-0.8176},{"period":"6month","weight":-0.8176},{"period":"1year","weight":-0.8176},{"period":"ytd","weight":-0.8176}],"compareEarnings":[{"period":"1week","weight":-0.0263},{"period":"1month","weight":-0.0526},{"period":"3month","weight":-0.0539},{"period":"6month","weight":-0.0074},{"period":"1year","weight":0.1378},{"period":"ytd","weight":-0.0421}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Lpath, Inc.是一家生物科技公司，專註於脂類基礎治療性抗體的開發與研究，這是一個醫療科學的新興領域，針對帶有生物活性的信號脂質來治療一系列人類疾病。公司目前有兩個候選產品位於臨床開發階段，一個產品位於臨床前評估階段。 Lpath, Inc是發現和開發中和生物活性脂質的單克隆抗體的行業領跑者。脂質研究（稱作lipidomics）是一個新興研究領域，目前已經發現的具有生物活性會促成疾病的有幾十個，如果在該領域的資金繼續投入的話，還將有數百個相關發現。一旦引起疾病的脂質確定下來接下來的挑戰就是生產一種能中和相關生物活性脂質的複合物。通過其免疫Y2平台技術和強大的專利財產，Lpath處在唯一能夠面對這些挑戰，利用機遇的地位。","exchange":"NASDAQ","name":"Lpath","nameEN":"Lpath"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"LPTN\",market:\"US\",,,undefined,":null}}